News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shield Therapeutics Announces Acceptance Of ST10 Abstract For Presentation At ECCO Congress 2014



2/4/2014 12:45:28 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

London, UK, 4th February 2014. Shield Therapeutics (Shield), an independent specialty pharmaceutical company, today announces the acceptance of the first peer-reviewed abstract relating to data from the AEGIS Phase III programme of ST10 for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD). The data will be presented at the 9th Congress of ECCO, taking place from February 20 – 22 in Copenhagen, Denmark.

As recently announced, ST10, a novel orally-dosed form of ferric iron, successfully met both the primary and secondary endpoints of the AEGIS pivotal Phase III programme. With a mean increase of 2.3g/dL in ST10-treated subjects, the results of the study strongly demonstrated ST10’s potential to be the only effective oral treatment for ferrous intolerant IDA patients, in addition to being an effective alternative to intravenous iron treatment.

The abstract about ST10, entitled “Correcting iron deficiency anaemia in IBD: A pivotal phase 3 study of a novel oral ferric iron”, will be presented during the Digital Oral Poster Session 9 - Therapy today – in Room 9, Hall B on the Ground level of the Bella Centre at 13.07 on Friday 21st February 2014.

For more information about Shield Therapeutics, please contact:

Consilium Strategic Communications
Mary-Jane Elliott / Emma Thompson / Lindsey Neville
Tel +44 (0)20 7920 2333
Email: shieldtherapeutics@consilium-comms.com

About Shield Therapeutics
Shield Therapeutics (www.shieldtherapeutics.com), founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. Shield has successfully completed a pivotal Phase 3 programme of its lead asset, ST10, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and is soon to commence a Phase 3 study of ST10 for the treatment of iron deficiency anaemia in patients with chronic kidney disease.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES